Voquezna (Vonoprazan Fumarate) Patent Expiration, LOE Window & CMS Spending

Voquezna (Vonoprazan Fumarate) by Phathom: FDA Orange Book core substance LOE 2030-04-10 (last listed 2032-05-03), 0 AB generics, $41.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPhathom
FDA Application & PathwayN215151 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-04-10
Last Listed Patent or Exclusivity Date2032-05-03
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$41.6M
2024 Medicare Part D Spend$31.3M
2024 Medicaid Spend$10.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel